The management of borderline epithelial tumors of the ovary

International Journal of Gynecological Cancer

Volumn 10, Issue 3, 2000, Pages 181-197

  Burger, C W ^a   Prinssen, H M ^b   Baak, J P A ^b,c   Wagenaar, N ^b   Kenemans, P ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

Borderline; Ovarian neoplasms; Tumor of low malignant potential

Indexed keywords

CA 125 ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; ONCOGENE; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SECOND LOOK SURGERY; TUMOR SUPPRESSOR GENE;

EID: 0033871761     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.010003181.x     Document Type: Article

References (191)

1. Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in the Netherlands
2. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary
3. Borderline epithelial tumors of the ovary: A conceptual dilemma
4. Epithelial ovarian carcinoma of low malignant potential
5. Borderline tumors of the ovary
6. Epidemiology of borderline ovarian tumors
7. Management of borderline tumors of the ovary: State of the art
8. The woman at risk for developing ovarian cancer
9. Ovarian neoplasm in the Western Cape
10. Tumors of low malignant potential
11. Management of epithelial ovarian tumors of low malignant potential
12. Clinical and histological studies of ovarian carcinoma. Long-term follow-up of 990 cases
13. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities
14. Long-term follow-up of serous ovarian tumors of low malignant potential
15. Risk factors for epithelial ovarian tumors of borderline malignancy
16. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women
17. Factors in causation and incidence of ovarian cancer
18. 'Incessant ovulation' and ovarian cancer
19. Case-control study of borderline ovarian tumors: Reproductive history and exposure to exogenous female hormones
20. Ovarian carcinoma in a patient stimulated by gonadotropin therapy for IVF: A case report
21. Borderline malignancy of the ovary and controlled hyperstimulation: A report of 2 cases
22. Ovarian carcinoma of low malignant potential, infertility and induction of ovulation - Is there a link?
23. Ovarian tumors in a cohort of infertile women
24. Cosmetic talc and ovarian cancer
25. Ovarian cancer and talc: A case control study
26. A case-control study of borderline ovarian tumors: The influence of perineal exposure to talc
27. Ovarian cancer of low malignant potential is not associated with positive familial history (letter)
28. Familial ovarian cancer: A population-based case-control study
29. Familial ovarian cancer: A population-based case-control study
30. Investigation of ovarian neoplasia of low malignant potential for human papillomavirus
31. Genital-type human papillomavirus infection is not associated with surface epithelial ovarian carcinoma
32. Prognostic significance of p53 immunostaining in epithelial ovarian cancer
33. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors
34. P53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry
35. P53 mutation is a common genetic event in ovarian carcinoma
36. Expression of p53 protein in borderline epithelial ovarian tumors: A clinicopathologic study of 39 cases
37. P53 Mutation in a series of epithelial ovarian cancers from the U.K. and its prognostic significance
38. Immunostaining of p53 protein in ovarian carcinoma: Correlation with histopathological data and clinical outcome
39. P53 and HER-2/neu overexpression in ovarian borderline tumors
40. Expression of cell regulatory proteins in ovarian borderline tumors
41. Borderline tumors of the ovary: A clinico-pathologic and immunohistochemical study of 54 cases
42. K-ras mutations in nonmucinous ovarian epithelial tumors: A molecular analysis and clinicopathologic study of 144 patients
43. Human ovarian cancer of the surface epithelium
44. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary
45. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families
46. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors
47. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors
48. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors
49. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas
50. Ovarian epithelial tumors of borderline malignancy
51. Low malignant potential tumors of the ovary: 76 Cases
52. Ovarian epithelial tumors of borderline malignancy in Japan
53. Clinical aspects of ovarian tumors of low malignant potential
54. Primary peritoneal carcinoma: A review of the literature
55. Epithelial tumors of the ovary: CT findings and correlation with US
56. Epithelial tumors of the ovary: Comparison of MR and CT findings
57. Borderline ovarian malignancy: Ultrasound and fast dynamic MR findings
58. Ultrasound examination for detection of ovarian carcinoma in risk groups
59. Sonographic and Doppler flow characteristics of ovarian tumors of low malignant potential
60. Symposium: Ovarian tumors of borderline malignancy
61. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass
62. Macroscopic characterization of ovarian tumors and the relation to histological diagnosis: Criteria to be used for ultrasound evaluation
63. Epithelial ovarian carcinoma of low malignant potential
64. Ovarian tumors of low malignant potential: Transvaginal Doppler ultrasound features
65. The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analysis
66. Pre-operative morphological and color Doppler features of borderline ovarian tumors
67. Elevated CA 125 levels prior to diagnosis of ovarian neoplasia. Relevance for early detection of ovarian cancer
68. Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumor marker in relation to CA125 and TPA for ovarian epithelial tumors
69. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor
70. CA125 in gynecological pathology: A review
71. Recurrent serous borderline tumors of the ovary
72. World Health Organization classification and nomenclature of ovarian cancer
73. The pathological assessment of ovarian neoplasms. II: The roliferating epithelial tumors
74. Preserving ovarian function in the treatment of epithelial and special (other) malignant ovarian tumors
75. Cellular DNA content as a new prognostic tool in patients with tumors of the ovary
76. Borderline ovarian tumors
77. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior
78. Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment
79. Disagreement of pathological diagnosis of different pathologists in ovarian tumors with some theoretical considerations
80. Interobserver variability in the interpretation of epithelial ovarian cancer
81. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing
82. Observer variation in histologic classification of malignant and borderline ovarian tumors
83. Grading ovarian tumors. Evaluation of decision making by different pathologists
84. Ovarian serous borderline tumors with stromal microinvasion: A report of 21 cases
85. Serous tumors of low malignant potential with early stromal invasion. (Serous LMP with micro-invasion)
86. Microinvasion in low malignant potential tumors of the ovary
87. The behavior of serous tumors of low malignant potential: Are they ever malignant?
88. A nuclear DNA content of borderline tumors of the ovary: Correlation with histology and significance for prognosis
89. Nuclear DNA heterogeneity of ovarian borderline malignant serous tumors
90. The role of DNA cytoflowmetry in borderline malignant ovarian tumors
91. Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors
92. DNA cytophotometery and prognosis in ovarian tumors of borderline malignancy
93. DNA ploidy - The most important prognostic factor in patients with borderline tumors of the ovary
94. Clinical value of new techniques of gynecological tumor assessment
95. Histological discrimination of malignancy in mucinous ovarian tumors
96. Quantitation of borderline and malignant mucinous ovarian tumours
97. The prognostic value of morphometry in ovarian epithelial tumors of border line malignancy
98. Morphometric data in the prognosis of ovarian tumours, in addition to FIGO stage, histologic type and grade
99. Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma
100. Ovarian tumors of low malignant potential (borderline tumors): Immune morphology and current status
101. Use of CA125 monoclonal antibody to monitor patients with ovarian cancer
102. Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors
103. Ki 67 expression in 35 borderline ovarian tumours: Relations with clinicopathologic parameters and ploidy
104. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: Comparison with cystadenomas and overt carcinomas
105. CD31 expression in benign, borderline, and malignant epithelial ovarian tumors: An immunohistochemical and serological analysis
106. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary
107. E-cadherin expression in human epithelial ovarian cancer and normal ovary
108. 72-KiloDalton type IV collagenase, type I collagen, and Ki 67 antigen in serous tumor of the ovary: A clinicopathologic, immunohistochemical, and serological study
109. PS2 and PAI-1 in ovarian cancer: Correlation to pathohistological parameters
110. Estrogen receptor expression is a common feature of ovarian borderline tumors
111. The concept of borderline malignancy in ovarian tumors: A reappraisal
112. Borderline tumors of the ovary: Histological and cytological features
113. Ovarian epithelial tumors of borderline malignancy pathological features and current status
114. The biological behavior of low grade papillary serous carcinoma of the ovary
115. Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential)
116. Peritoneal lesions associated with proliferative serous tumors of the ovary
117. Proliferative serous tumors of the ovary. Histologic features and prognosis
118. Peritoneale epitheelproliferaties bij sereuze borderline tumoren van het ovarium
119. Zur klinischen problematik von serosen borderline ovarialtumoren
120. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors
121. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis
122. Ovarian mucinous tumors of low malignant potential: A clinico pathologic study of 54 tremors of intestinal and mullerian type
123. Responses of a mucinous ovarian tumor of borderline malignancy to human chorionic gonadotropin
124. Morphology of ovarian cystadenoma: Surface ultrastructure, development and biologic behavior
125. Borderline and malignant mucinous tumors of the ovary: Histologic criteria and clinical behavior
126. Serous ovarian tumors of low malignant potential with peritoneal implants
127. Pseudomyxoma peritonei in women: A clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential
128. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women
129. Genetic analysis of synchronous mucinous tumors of the ovary and appendix
130. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma perotonei: Histogenetic implications of cytokeratin 7 expression
131. Ovarian cancer metastatic to the breast
132. Invasive and non-invasive implants in ovarian serous tumors of low malignant potential
133. Papillary carcinoma of the ovary
134. Multifocal tumorigenesis in the upper female genital tract: Implications for stagement and management
135. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families
136. Conservative surgery for stage I ovarian carcinoma in women of childbearing age
137. Management of ovarian neoplasms of low malignant potential
138. Borderline epithelial ovarian tumors
139. Epithelial ovarian tumors of borderline malignancy: Long-term follow-up
140. Current concepts in management of epithelial ovarian tumors of low malignant potential
141. Prognosis and management of borderline tumors of the ovary
142. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma
143. Ovarian cystectomy for serous borderline tumors: A follow up study of 35 cases
144. Peritoneal washing cytology in gynecologic cancers: Long-term follow-up of 335 patients
145. Conservative treatment of borderline ovarian tumors
146. Epithelial tumors of borderline malignancy: A study of 50 cases
147. Recurrent borderline tumors after conservative treatment management in women wishing to retain their fertility
148. The accuracy of a frozen section diagnosis of borderline ovarian malignancy
149. The accuracy of frozen section by tumor weight for ovarian epithelial neoplasms
150. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors
151. Peri-ovarian adhesions following wedge resection or laparoscopic biopsy
152. The efficacy of interceed (TC7) for prevention of reformation of postoperative adhesions on ovaries, fallopian tubes, and fimbriae in microsurgical operations for fertility: A multicentre study
153. Preservation of ovarian function and reproductive ability in patients with malignant ovarian tumors
154. Staging laparotomy in early epithelial ovarian carcinoma
155. Primary staging in ovarian tumors of low malignant potential
156. Evaluation of surgical staging in stage I low malignant potential ovarian tumors
157. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential
158. The current status of surgical staging of ovarian serous borderline tumors
159. Ovarian serous borderline epithelial tumors with multiple retroperitonal nodal involvement: Metastases or malignant transformation of epithelial glandular inclusions?
160. Laparoscopic excision of ovarian neoplasms subsequently found to be malignant
161. Laparoscopic management of malignant ovarian cysts: A 78-case national survey Part I: Pre-operative and laparoscopic evaluation
162. Laparoscopically assisted hysterectomy for the management of a borderline ovarian tumor: A case report
163. Abdominal wall metastases from ovarian cancer after laparoscopy
164. Laparoscopic management of ovarian tumors
165. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study)
166. Serous borderline tumors of the ovary with noninvasive peritoneal implants
167. Cisplatin based combination chemotherapy in the treatment of stage Ill ovarian epithelial tumors of low malignant potential
168. Adjuvant treatment in ovarian carcinoma with no residual disease following surgery
169. Stage I borderline ovarian tumors
170. Ovarian carcinoma of low malignant potential: Staging and treatment
171. Platinumbased chemotherapy for advanced stage of serous ovarian carcinoma of low malignant potential
172. Borderline epithelial tumors of the ovary
173. Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
174. The second-look operation and surgical reexploration in ovarian tumor of low malignant potential
175. The outlook for women with borderline epithelial tumor of the ovary
176. Computerized image analysis and flow cytometric evaluation of ovarian borderline tumors: A study of 24 cases
177. DNA flow cytometric analysis of serous ovarian tumors of low malignant potential
178. The prognostic significance of grading in borderline mucinous tumors of the ovary
179. Ovarian serous borderline tumors with invasive peritoneal implants
180. An assessment of pathologic features and treatment modalities in ovarian tumor of low malignant potential
181. Epithelial ovarian carcinoma of low malignant potential
182. Ovarian tumors of low malignant potential: A retrospective study of 234 patients
183. Borderline tumors of the ovary. Fertility treatment, conservative management, and pregnancy outcome
184. Epithelial ovarian tumors of low malignant potential
185. Annual report on the results of treatment in gynecological cancer
186. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 54 advanced stage cases
187. Clinical behavior of borderline ovarian tumors: A study of 150 cases
188. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993